Product Launchenzyme substitutionrare diseasesbiomarinfda approval
BioMarin Expands PALYNZIQ Use To Adolescents
6.6
BioMarin announced that on February 27 the US FDA approved a supplemental Biologics License Application expanding PALYNZIQ use to adolescents aged 12 and older with phenylketonuria (PKU). The approval, supported by Phase 3 PEGASUS data showing statistically significant reductions in blood phenylalanine, retains a consistent safety profile and is subject to a REMS program; BioMarin is pursuing a similar EU label expansion.
Key Points
- 1Announces FDA approval expanding PALYNZIQ to adolescents aged 12 and older via supplemental BLA
- 2Validates efficacy: Phase 3 PEGASUS showed statistically significant blood Phe reductions compared with diet alone
- 3Impacts treatment access: REMS-managed therapy offers enzyme substitution option reducing adolescent neurocognitive risk
Scoring Rationale
Official FDA approval provides verifiable clinical and commercial advancement, but impact remains niche to the PKU patient population.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
